350 related articles for article (PubMed ID: 20023922)
1. Synthesis, molecular structure and evaluation of new organometallic ruthenium anticancer agents.
Camm KD; El-Sokkary A; Gott AL; Stockley PG; Belyaeva T; McGowan PC
Dalton Trans; 2009 Dec; (48):10914-25. PubMed ID: 20023922
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, characterization and antitumor properties of two highly cytotoxic ruthenium(iii) complexes with bulky triazolopyrimidine ligands.
Łakomska I; Fandzloch M; Muzioł T; Lis T; Jezierska J
Dalton Trans; 2013 May; 42(17):6219-26. PubMed ID: 23328694
[TBL] [Abstract][Full Text] [Related]
3. A novel ruthenium(III) complex with a tridentate dianionic P,O,O-ligand showing high cytotoxic activity.
van Rijn JA; Marqués-Gallego P; Reedijk J; Lutz M; Spek AL; Bouwman E
Dalton Trans; 2009 Dec; (48):10727-30. PubMed ID: 20023901
[TBL] [Abstract][Full Text] [Related]
4. DNA cleavage and antitumour activity of platinum(II) and copper(II) compounds derived from 4-methyl-2-N-(2-pyridylmethyl)aminophenol: spectroscopic, electrochemical and biological investigation.
Roy S; Maheswari PU; Lutz M; Spek AL; den Dulk H; Barends S; van Wezel GP; Hartl F; Reedijk J
Dalton Trans; 2009 Dec; (48):10846-60. PubMed ID: 20023915
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative activity of dmoPTA-Ru(II) complexes against human solid tumor cells.
Ríos-Luci C; León LG; Mena-Cruz A; Pérez-Roth E; Lorenzo-Luis P; Romerosa A; Padrón JM
Bioorg Med Chem Lett; 2011 Aug; 21(15):4568-71. PubMed ID: 21719285
[TBL] [Abstract][Full Text] [Related]
6. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
[TBL] [Abstract][Full Text] [Related]
7. Anticancer activity of opened arene ruthenium metalla-assemblies.
Barry NP; Zava O; Furrer J; Dyson PJ; Therrien B
Dalton Trans; 2010 Jun; 39(22):5272-7. PubMed ID: 20442944
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, oxidation chemistry and cytotoxicity studies on ferrocene derivatives of diethylstilbestrol.
Tan YL; Pigeon P; Hillard EA; Top S; Plamont MA; Vessières A; McGlinchey MJ; Müller-Bunz H; Jaouen G
Dalton Trans; 2009 Dec; (48):10871-81. PubMed ID: 20023917
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological studies of some gold(I) complexes containing functionalised alkynes.
Schuh E; Valiahdi SM; Jakupec MA; Keppler BK; Chiba P; Mohr F
Dalton Trans; 2009 Dec; (48):10841-5. PubMed ID: 20023914
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, characterization, and in vitro evaluation of a potentially selective anticancer, mixed-metal [ruthenium(III)-platinum(II)] trinuclear complex.
Herman A; Tanski JM; Tibbetts MF; Anderson CM
Inorg Chem; 2008 Jan; 47(1):274-80. PubMed ID: 18062685
[TBL] [Abstract][Full Text] [Related]
11. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
12. Non-classical anticancer agents: synthesis and biological evaluation of zinc(II) heteroleptic complexes.
Liguori PF; Valentini A; Palma M; Bellusci A; Bernardini S; Ghedini M; Panno ML; Pettinari C; Marchetti F; Crispini A; Pucci D
Dalton Trans; 2010 May; 39(17):4205-12. PubMed ID: 20390185
[TBL] [Abstract][Full Text] [Related]
13. Synthetic strategies towards ruthenium-porphyrin conjugates for anticancer activity.
Gianferrara T; Bratsos I; Iengo E; Milani B; Ostrić A; Spagnul C; Zangrando E; Alessio E
Dalton Trans; 2009 Dec; (48):10742-56. PubMed ID: 20023904
[TBL] [Abstract][Full Text] [Related]
14. Markedly different cytotoxicity of the two enantiomers of C(2)-symmetrical Ti(IV) phenolato complexes; mechanistic implications.
Manna CM; Tshuva EY
Dalton Trans; 2010 Feb; 39(5):1182-4. PubMed ID: 20104339
[TBL] [Abstract][Full Text] [Related]
15. Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties.
Pelletier F; Comte V; Massard A; Wenzel M; Toulot S; Richard P; Picquet M; Le Gendre P; Zava O; Edafe F; Casini A; Dyson PJ
J Med Chem; 2010 Oct; 53(19):6923-33. PubMed ID: 20822096
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, single-crystal and solution structure analysis and in vitro cytotoxic activity of two novel complexes of ruthenium(II) with in situ formed flavanone-based ligands.
Ochocki J; Kasprzak M; Chęcińska L; Erxleben A; Zyner E; Szmigiero L; Garza-Ortiz A; Reedijk J
Dalton Trans; 2010 Oct; 39(40):9711-8. PubMed ID: 20830400
[TBL] [Abstract][Full Text] [Related]
17. Dual anti-angiogenic and cytotoxic properties of ruthenium(III) complexes containing pyrazolato and/or pyrazole ligands.
Sun RW; Ng MF; Wong EL; Zhang J; Chui SS; Shek L; Lau TC; Che CM
Dalton Trans; 2009 Dec; (48):10712-6. PubMed ID: 20023898
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, characterization, and cytotoxicity of dinuclear platinum-bisphosphonate complexes to be used as prodrugs in the local treatment of bone tumours.
Margiotta N; Ostuni R; Gandin V; Marzano C; Piccinonna S; Natile G
Dalton Trans; 2009 Dec; (48):10904-13. PubMed ID: 20023921
[TBL] [Abstract][Full Text] [Related]
19. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, structure and biological evaluation of bis salicylaldehyde-4(N)-ethylthiosemicarbazone ruthenium(iii) triphenylphosphine.
Prabhakaran R; Kalaivani P; Jayakumar R; Zeller M; Hunter AD; Renukadevi SV; Ramachandran E; Natarajan K
Metallomics; 2011 Jan; 3(1):42-8. PubMed ID: 21132183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
